Skip to main content
Clinical Trials/NCT00491309
NCT00491309UnknownNot Applicable

Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension

Heidelberg University1 site in 1 country45 target enrollmentStarted: July 1, 2011Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
45
Locations
1
Primary Endpoint
Change in the 6-minute walking distance

Study Overview

Brief Summary

In Patients with rheumatic disease exercise training is a well established element of therapy. In contrast patients with severe pulmonary hypertension are advised to avoid physical exertion and must not perform exercise training. This study aims to evaluate the effectivity and safety of a low-dose training program in patients with pulmonary hypertension and rheumatic disease.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Informed consent
  • •Men and women 18 - 80 years
  • •Diagnosed rheumatic disease: rheumatoid arthritis, Collagenosis (Systemic Lupus Erythematodes, Systemic Sclerosis, Sjögren-Syndrome, Sharp-Syndrome, Crest-Syndrome, Mixed connective tissue disease)
  • •Symptomatic PAH (WHO- functional class II-IV) invasively diagnosed by right heart catheterisation
  • •Mean pulmonary artery pressure (mPAP) > 25 mmHg
  • •Pulmonary capillary wedge pressure (PCWP) > 15 mmHg
  • •Pulmonary vascular resistance (PVR) at baseline >320 dyn.sec/cm5 patients under optimized medical treatment since at least 2 ½ months

Exclusion Criteria

  • •Other forms of PAH.
  • •Pregnancy or lactation
  • •Change in medication during the last 2 ½ months
  • •Patients with signs of right heart decompensation
  • •Severe impairment of walking
  • •Unclear diagnosis
  • •No invasive diagnosis of PH
  • •Acute illness, infection, fever
  • •Severe lung disease with FEV1 <50% and TLC< 70% below reference

Arms & Interventions

exercise training group

Active Comparator

exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)

Intervention: exercise training (Behavioral)

Control group without exercise training

No Intervention

continuation of sedentary lifestyle without advice for specific exercise training

Outcomes

Primary Outcomes

Change in the 6-minute walking distance

Time Frame: after 3 weeks and after 15 weeks compared to baseline.

Quality of life (SF-36)

Time Frame: baseline and 15 weeks

Secondary Outcomes

  • Physical capacity in the cardiopulmonary exercise testing (Watt)(baseline, 3 weeks, 15 weeks)
  • change of peak oxygen consumption and other parameters of cardiopulmonary exercise testing.(baseline, 3 weeks, 15 weeks)
  • hemodynamic parameters: dimension and pump function of the right and the left ventricle.(baseline, 15 weeks)
  • change in systolic pulmonary arterial pressure at rest and during exercise(baseline, 3 weeks, 15 weeks)
  • change in inflammatory parameters (BKS, CRP, Leucocytes), change in inflammatory cytokines (TNF-α), change in parameters of the vascular endothelium (Endothelin, PDGF, VEGF), and endothelial progenitor cells(baseline and 15 weeks)
  • change of NTproBNP-value(baseline, 3 weeks, 15 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. med. Ekkehard Gruenig

Prof. Dr. med. Ekkehard Grünig

Heidelberg University

Study Sites (1)

Loading locations...

Similar Trials